Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
1 other identifier
observational
86
1 country
1
Brief Summary
The sudy purpose is to investigate efficacy and safety of percutaneous endovascular aortic aneurysm repair using INCRAFT stent graft for Korean patients with abdominal aortic aneurysm. This study is designed as an investigator-initiated, multi-center, single-arm, prospective registry study. A total of 100 patients who meet all inclusion criteria, but none of exclusion criteria will be enrolled after the implantation of INCRAFT stent graft. The primary efficacy outcome is technical success defined as successful deployment of the stent-graft with no type I/III endoleak, unintentional coverage of visceral aortic branches or internal iliac arteries at the end of the procedure, and with successful removal of the delivery system. The primary safety outcome is major vascular complications at 30 days including. The study subjects will be followed for 12 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2019
CompletedFirst Posted
Study publicly available on registry
May 16, 2019
CompletedStudy Start
First participant enrolled
September 2, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 20, 2023
CompletedApril 5, 2024
April 1, 2024
4.1 years
May 14, 2019
April 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Technical success
Technical success defined as successful deployment of the stent-graft with no type I/III endoleak, unintentional coverage of visceral aortic branches or internal iliac arteries at the end of the procedure, and with successful removal of the delivery system. Primary conversion or additional implantation of bare metal stent, aortic cuff or EndoAnchors to treat type I endoleak is considered a technical failure.
At the end of the procedure
Secondary Outcomes (12)
Major adverse event
30 days
Major adverse event
1 year
Aneurysm-related death
30 days
Aneurysm-related death
1 year
Aneurysm-related death
30 days
- +7 more secondary outcomes
Eligibility Criteria
Patients with abdominal aortic aneurysm treated with INCRAFT stent graft
You may qualify if:
- \. AAA with one of following indications
- AAA with maximum diameter \> 5 cm,
- AAA with maximum diameter \> 4 cm with an increase \>0.5 cm during the preceding 6 months
- Saccular type AAA irrespective of the sac diameter.
- \. Proximal aortic neck length ≥10 mm with a diameter ≥ 17 and ≤ 31 mm in combination with supra- and infrarenal angulation ≤ 60 degree.
- \. Iliac landing zone with a length ≥15 mm and a diameter ≥ 7 and ≤ 22 mm
- \. Femoral access vessels should be adequate to fit the selected delivery system
- \. Minimum overall AAA treatment length (proximal landing location to distal landing location to distal landing location) ≥128 mm
- \. Aortic bifurcation \>18 mm in diameter
- \. Patents with age of 19-80 years.
- \. Male or non-pregnant female
- \. Voluntary participation in the study with signed informed consent form.
You may not qualify if:
- \. Dissecting or ruptured abdominal aortic aneurysm
- \. Presence of connective tissue disease (Marfan's syndrome or Ehlers-Danlos syndrome).
- \. Prior AAA or iliac artery repair
- \. Active infection or active vasculitis.
- \. Myocardial infarction or cerebrovascular accident within 3 months prior to study enrolment.
- \. Need for renal artery coverage (e.g. Chimney graft)
- \. Dialysis-dependent renal failure or serum creatinine \>2.0 mg/dl
- \. Intolerance/hypersensitivity to contrast media or antiplatelet drugs.
- \. Positive pregnancy test.
- \. Participation in another medical research study within 1 month of study enrolment.
- \. Planned concomitant surgical procedures (other than left subclavian artery transposition or bypass) or major surgery within 30 days of study enrolment.
- \. Patients with life expectancy less than 1 year
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2019
First Posted
May 16, 2019
Study Start
September 2, 2019
Primary Completion
September 20, 2023
Study Completion
September 20, 2023
Last Updated
April 5, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share